Best deal of the week
DR. DOPING

Instructions

Logo DR. DOPING

Instruction for use: Brizantine

I want this, give me price

Dosage form: lozengers

ATX

N07BA Drugs for the treatment of nicotine dependence

Pharmacological group:

Nicotine dependence means of treatment [Other immunomodulators]

The nosological classification (ICD-10)

F17.2 Nicotine addiction: Craving for smoking; Attraction to smoking tobacco; Tobacco dependence; Abstinence syndrome with smoking cessation; Abuse of nicotine

F17.3 Abstinence due to tobacco use: Nicotinic abstinence; syndrome with smoking cessation

Z72.0 Tobacco use: tobacco smoking, Smoking

Composition

Tablets for resorption 1 table.

Active substances: Antibodies to the brain-specific protein S-100 affinity purified * 0.006 g

Antibodies to cannabinoid receptor type 1 affinity purified * 0.006 g

Auxiliary substances: lactose monohydrate; MCC; Magnesium stearate

* They are applied to lactose in the form of a mixture of three active aqueous-alcohol dilutions of the substance diluted 10012, 10030, 100200 times, respectively

Description of dosage form

Tablets are flat-cylindrical with a risk and facet, from white to almost white. On the side with the risk there is an inscription "MATERIA MEDICA", on the other - the inscription "BRIZANTIN".

Pharmachologic effect

Mode of action - Immunomodulating.

Pharmacodynamics

Combined drug.

Antibodies to the brain-specific protein S-100 have antioxidant, antihypoxic, neuroprotective, anxiolytic, antidepressant action. Modify the functional activity of the S-100 protein, which conjugates information and metabolic processes in the brain. They have a membrane-effect effect, causing a decrease in the amplitude and suppression of the generation of the action potential; Modulate the synaptic transmission in the limbic structures of the brain, the hippocampus, the reticular formation; Contribute to the enhancement of inhibitory effects of GABA in the central nervous system. They demonstrate the properties of the Σ1 receptor agonist in vitro.

Inhibit the processes of lipid peroxidation.

Antibodies to the cannabinoid receptor type 1 modulate the functional activity of the cannabinoid receptor type 1, affect the concentration of intracellular cAMP. Regulate the endocannabinoid system in the central nervous system (mainly in neurons of the mesolimbic system) and peripheral tissues, normalize the energy balance (glucose and lipid metabolism). Experimentally, the models of self-stimulation of the lateral hypothalamus show a synergistic addictive effect when both components are used together in the complex preparation Bryzantine.

Brizantine modulates the system of positive emotional reinforcement, thereby reducing the severity of the craving for psychoactive substances in alcoholism and nicotinism; Normalizes the balance of neurotransmitters in the central nervous system. Brizanthin also exhibits neuroprotective activity, improves brain resistance to toxic effects, improves integrative activity, helps to eliminate cognitive impairment, increases mental performance, normalizes somatovegetative manifestations with abstinence conditions.

The drug eliminates affective (irritability, decreased mood, internal discomfort), ideator (thoughts of nicotine or alcohol) and asthenovegetative disorders (pronounced general weakness, decreased efficiency, appetite, sweating, tachycardia). It leads to a decrease in the number of cigarettes smoked and the dose of nicotine consumption. Reduces anxiety amid quitting smoking.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of ultra-small doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of the Brizantine preparation.

Indications of the Brizantine

The drug is used to reduce the craving for nicotine both in the first days of refusal to take it (the period of withdrawal), and with the impulsively manifested desire to use it.

Contraindications

Increased individual sensitivity to the components of the drug;

Children under 18 years of age (due to insufficient data on effectiveness and safety for this age).

Application in pregnancy and breastfeeding

The safety of the use of Brizantine during pregnancy and during lactation has not been studied. If necessary, taking the drug should take into account the risk / benefit ratio.

Side effects

Possible reactions of increased individual sensitivity to the components of the drug.

Interaction

Cases of incompatibility with other drugs have not been recorded so far.

Dosing and Administration

Inside, out of the way of food (keep in your mouth until completely dissolved). At one time - 1 table. Apply to 1 tab. 2-3 times a day. With increasing craving for nicotine, it is possible to increase the frequency of admission to 5-6 times a day. The recommended course of taking the drug is 3 months.

Overdose

In case of an accidental overdose, dyspeptic events due to the excipients included in the formulation are possible.

Special instructions

The composition of the drug includes lactose, and therefore it is not recommended to appoint patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase insufficiency.

Impact on the ability to drive vehicles and other potentially dangerous mechanisms. Does not affect.

Release form

Lozenges. For 20 tablets. In a planar cell packaging made of PVC film and aluminum foil.

For 1, 2 or 5 contour squares are placed in a pack of cardboard.

Manufacturer

OOO NPF Materia Medica Holding.

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Brizantine

In the dark place at a temperature of no higher than 25 C.

Keep out of the reach of children.

Shelf life of the drug Brizantine

3 years.

Do not use after the expiry date printed on the package.

Someone from the Canada - just purchased the goods:
Complex of cytamins for the endocrine system